Comparative Pharmacokinetics and Safety of Cannabidiol in a Powder Formulation, CBtru
| Journal | CNS drugs |
| Study Type | Randomized Trial |
| Population | Human participants |
Bioavailability remains a critical challenge in CBD therapeutics, with poor absorption limiting clinical efficacy and dose predictability. This head-to-head pharmacokinetic comparison provides essential data for clinicians selecting between CBD formulations for patients.
This Phase I randomized crossover trial compared a powdered emulsion CBD formulation (CBtru) against oil-based CBD in healthy adults, administering single 400mg doses under fasted and fed conditions. The powdered formulation demonstrated superior bioavailability under fasted conditions compared to oil-based CBD, with both formulations showing distinct pharmacokinetic profiles that varied significantly between fasted and fed states. The study establishes safety profiles for both formulations while highlighting the critical impact of food intake on CBD absorption across different delivery methods.
“This represents meaningful progress in addressing CBD’s bioavailability challenges, though I remain cautious about extrapolating single-dose pharmacokinetics to chronic dosing scenarios. The food effect data reinforces my clinical practice of providing specific dosing instructions relative to meals.”
💬 Join the Conversation
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What is CBtru and how does it differ from traditional CBD formulations?
- Does food intake affect CBD absorption with this new formulation?
- What dose was studied and is this clinically relevant for patient care?
- How safe is this new CBD formulation based on the study results?
- What are the clinical implications for prescribing CBD given these formulation differences?
- Read next
FAQ
What is CBtru and how does it differ from traditional CBD formulations?
CBtru is an encapsulated powdered emulsion formulation of cannabidiol that aims to overcome the low oral bioavailability challenges of pure CBD. Unlike traditional oil-based CBD formulations typically used due to CBD’s high lipophilicity, this powder formulation demonstrated distinct pharmacokinetic profiles and may offer improved dosing convenience and stability.
Does food intake affect CBD absorption with this new formulation?
Yes, this study confirmed that both CBtru and traditional formulations demonstrate distinct pharmacokinetic profiles under fasted versus fed conditions. The food effect on CBD absorption remains clinically significant and should be considered when dosing patients, regardless of the formulation type used.
What dose was studied and is this clinically relevant for patient care?
The study evaluated a single 400-mg dose of CBtru in healthy adults using a randomized crossover design. This dose falls within the therapeutic range used clinically for various conditions, making the pharmacokinetic and safety findings directly applicable to clinical practice.
How safe is this new CBD formulation based on the study results?
The study evaluated tolerability and safety of the CBtru formulation in healthy adults as part of this Phase I trial. While specific safety outcomes aren’t detailed in the summary, the completion of this controlled trial suggests an acceptable safety profile, though clinicians should await full publication for comprehensive safety data.
What are the clinical implications for prescribing CBD given these formulation differences?
This research highlights that different CBD formulations have distinct pharmacokinetic profiles, which may impact therapeutic efficacy and dosing strategies. Clinicians should consider formulation-specific absorption characteristics when prescribing CBD and may need to adjust dosing when switching between different CBD products.
